Search

Search results

61 results found

ONL Therapeutics Announces Formation of Scientific Advisory Board

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and...

Author Response: Comparison of Risk Factor Profiles for Primary Open-Angle Glaucoma Subtypes Defined by Pattern of Visual Field Loss: True Risk Factors or Arbituary Definition?

Kang, Jae, Stephanie Loomis, Bernard Rosner, Janey Wiggs, and Louis Pasquale. 2015. “Author Response: Comparison of Risk Factor Profiles for Primary Open-Angle Glaucoma Subtypes Defined by Pattern of Visual Field Loss: True Risk Factors or Arbituary Definition?”. Invest Ophthalmol Vis Sci 56 (11): 6532-3.